Home Options SPOTReports

SPOT

Spotify Technology S.A.Close $433.32EOD only

Max Pain

$440.00

Next expiry May 22, 2026

Expected Move

±$25.02

5.8% from close

Price Gap

+6.68

Distance to max pain

IV Rank

Middle-high premium

P/C OI

1.17

Slightly put-heavy

Consensus

4/4

Partial coverage

Published snapshot: May 20, 2026 close

End-of-day snapshot

This page reflects SPOT options positioning from the latest published market-close snapshot. Intraday price and contract changes are not displayed.

Published Snapshot

May 20, 2026 close

SPOT Directional Report

Analysis based on market close March 31, 2026

Directional Theta Gang Flow Earnings Consensus

Historical consensus-supported lens with full content, report chain context, and metric rail.

Outlook

Neutral with a slight upward bias toward the $490-$500 zone, but trapped in a wide, high-volatility range. Confidence: 5.5/10. The regime is contradictory: positive GEX suggests pinning, but net negative premium and mixed flow signal underlying uncertainty. Spot is caught between near-term max pain magnets and distant structural OI walls.

Confidence:

5.5 / 10

Base 5.5 stands. +1 for GEX pinning near spot; -0.5 for net premium flow contradicting bullish pin; -0.5 for extremely high IV (59%) adding noise; +0.5 for spot proximity to near-term max pain.

Supports: Positive GEX (+$559K) and DEX (+3.9M shares) support pinning. Spot is within 1% of 3/27 max pain ($490).
Conflicts: Net premium flow is negative (-$18.8M) despite positive GEX. IV is extremely elevated at 59%, suggesting high uncertainty. P/C ratios are neutral (1.06 vol, 1.02 OI).

⚠️Extreme IV (59%) dominates all strategies — premium selling has edge but high risk.

📌Spot pinned between $490 (3/27) and $477.5 (4/2) max pain levels.

Regime Classification

Vol Regime

High

IV 59% is extremely high — favors premium selling and defined-risk spreads over long vol.

Gamma Regime

Pinning

GEX +$559K is positive but small relative to price, indicating mild pinning pressure near spot, not a strong magnet.

Flow Regime

Mixed

Mixed — net premium negative suggests put buying or call selling, but P/C ratios are neutral, showing no clear directional consensus.

Spot vs Max Pain

Below

Spot $484.91 is below 3/27 MP ($490) but above 4/2 MP ($477.5), caught between conflicting near-term pins.

Thesis duration: Multi-week — Max pain ladder shows a rising trend from $477.5 to $500+ over the next month, and GEX sign is stable positive. The high-volatility, range-bound regime is likely to persist beyond a single expiry.

Price Range Forecast

Next 2 days

$468.39$501.44

Max pain at $490 for 3/27 expiry provides a mild upward pull. Break below $468.39 (2d EM low) invalidates.

Next 1 week

$456.59$513.24

Pinned between 4/2 and 4/24 max pain levels. A move above $513.24 (1w EM high) signals breakout.

Next 2 weeks

$446.99$522.84

Max pain rises to $500 by 4/24 and $520 by 6/18. Structural call OI at $540-$660 caps major rallies.

Key Levels

Max pain pins: $490 (2026-03-27); $478 (2026-04-02); $485 (2026-04-10)

EM guardrails: 2d $468.39/$501.44; 1w $456.59/$513.24

Support: $410.00 · $100.00 · $350.00

Resistance: $600.00 · $500.00 · $600.00

Gamma flip: ~$410.00 — Approx — based on put OI concentration of 2,079

Structural: **Call OI wall $540-$660** (OI 1,339-3,043) is a major upside cap. **Put floor $100-$410** (OI 1,718-2,079) is far below and not a near-term support; the $410 gamma flip is the first meaningful level.

Dealer Positioning (GEX/DEX)

GEX: $+559K

DEX: +3.9M shares

Gamma flip: ~$410 (Approx — based on put OI concentration of 2,079)

NTM gamma: Gamma flip at ~$410 is far below spot, indicating dealers are long gamma (hedging is stabilizing) only on a severe drop. Near-term, dealer hedging flows are minimal, offering little resistance to moves within the expected range.

IV Analysis

IV vs VIX: IV 59% is extreme — SPOT vol is rich vs. any broad market measure, creating a strong environment for selling premium.

Term structure: **Steeply inverted**: 2d IV 56.5% > 10d IV 43.0%. A major kink at 5/01 (IV 55.4%) likely prices the 4/28 earnings event. This supports selling near-term and buying longer-dated vol (calendar spreads).

Skew: **~13.5 vol-point differential** between 4/2 (56.5%) and 4/10 (43.0%) expiries — a prime setup for a short calendar (sell near, buy far) to capture the steep inversion decay.

Flow Analysis

Net premium: Net $-18.8M bearish, but P/C ratios are neutral (1.06 vol, 1.02 OI), indicating the bearish flow is not overwhelmingly one-sided.

Directional prints: $460P 4/17 vol 704 vs OI 256 (2.8x) at IV 45.9% — could be protective put buying or opening of bearish spreads. $240P 7/17 vol 350 vs OI 196 (1.8x) at IV 72.6% — likely a far OTM hedge or speculative lottery ticket.

Unusual: Massive net negative premium at ultra-high strikes ($700, $740 puts) — this is almost certainly **far OTM put selling** (premium collection), not directional bearish bets, explaining the net negative premium despite neutral P/C ratios.

Risks & Catalysts

!**Gamma flip at $410** — a break below this level could trigger accelerated selling due to dealer hedging.

!**Earnings on 4/28** — priced into the 5/01 IV kink (55.4%); expect massive vol crush post-event.

!**Extreme IV (59%)** — while good for sellers, it implies high underlying volatility risk; long options are expensive.

!**Low liquidity / moderate OI** — GEX and max pain signals are weaker than in mega-caps; wider spreads.

Strategy Viability

Strategy	Edge	Best Setup	Primary Risk
Iron condor	Moderate-Weak	Sell $460/$455P & $505/$510C, 4/17 expiry. Wings at 1w EM bounds.	GEX is positive, but VIX proxy >28 (IV 59%) adds tail risk. Defined risk helps.
Cash-secured put / put spread	Moderate-Strong	Sell $460/$455 put spread 4/17, or CSP at $460. Targets 1w EM low and below near-term max pain.	Break below $456.59 (1w EM low).
Covered call	Moderate	Own stock, sell $500C 4/24. At resistance from max pain and call OI.	Capped upside if stock rallies toward $500+.
Long calls	Weak	Avoid. IV 59% is punitive for long premium. If bullish, use spreads.	Vol crush and time decay.
Long puts / bear put spread	Moderate-Weak	If bearish, buy $480/$475 put spread 4/10. Defined risk below spot.	High IV and positive GEX work against it.
Calendar/diagonal spread	Strong	Short Calendar: Sell $485C 4/2 (IV 56.5%), Buy $485C 4/10 (IV 43.0%). Capture ~13.5 vol pts.	Directional move through short strike.
PMCC / LEAPS diagonal	Moderate-Strong	Buy $410C Jan 2027 (IV ~48.4%), sell $500C against it monthly (e.g., 4/24). Leverages long-term bullish max pain trend.	Capital intensive; stock stagnation.
Short stock	Weak	Not recommended. Positive GEX and rising max pain trend provide upward pressure.	Squeeze toward $490-$500.
Long stock	Moderate	Entry near $477.5 (4/2 max pain) with target $500. Aligns with multi-week max pain drift.	High beta and IV environment.

Top Plays

Short Put Spread

Sell $460/$455 Put Spread, 4/17 expiry

Capitalizes on high IV for premium sale, positive GEX pinning, and places short put at the 1-week expected move low ($456.59). Defined risk below the key gamma flip.

Credit: $1.10-$1.30

Max loss: $3.90

BE: $458.90

Mgmt: Take profit at 60-70% of max credit. Exit if spot closes below $456.59 (1w EM low).

Traders with a neutral-to-bullish bias seeking defined-risk income in a high-vol environment.

Short Calendar Call

Sell $485C 4/2, Buy $485C 4/10

Exploits the steep 13.5 vol-point inversion in term structure. Best if spot stays near $485 through 4/2 expiry. The extra week in the long leg improves risk/reward by providing continued long exposure after the expensive short vol decays.

Credit: $2.50-$3.50

Max loss: N/A

BE: Complex; manage on short leg decay.

Mgmt: Close when short leg IV collapses post-4/2 expiry or if spot moves >$5 away from $485. Roll short leg if challenged.

Volatility traders looking to capitalize on term structure mispricing with minimal directional bias.

PMCC (Diag. Call Spread)

Buy $410C Jan 2027, Sell $500C 4/24

Expresses a multi-week bullish thesis aligned with the rising max pain trend ($477.5 → $500+). The LEAPS provides low-time-decay exposure, while the short call generates income against the $500 resistance (max pain & call OI). Better than a naked long call due to cost basis reduction.

Debit: $75.00-$85.00

Max loss: Cost of LEAPS

BE: Stock price > (LEAPS cost + $500C credit) by Jan 2027

Mgmt: Roll short calls up and out monthly, targeting strikes near resistance. Close if long-term max pain trend breaks (e.g., spot < $470 for multiple weeks).

Investors with a multi-month bullish view and sufficient capital to deploy a LEAPS.

Watchlist Triggers

Entry Triggers

IFSpot dips to $477.5 (4/2 max pain) and holds → Enter long stock or sell $460/$455 put spread 4/17.

IFIV term structure remains inverted (>10 vol pts between 4/2 and 4/10) → Initiate short calendar: sell $485C 4/2, buy $485C 4/10.

Exit Triggers

EXITPost-4/28 earnings, IV on 5/01 expiry collapses >20% → Take profit on all short premium positions (put spreads, calendars).

EXITSpot closes above $513.24 (1w EM high) → Exit short call positions and consider long delta (stock, call spreads).

Tactical Summary

Primary thesis: High-volatility range trade with a multi-week bullish drift toward $500. Favor selling premium (puts, calendars) due to extreme IV, using expected move bounds and max pain levels for strike selection. Invalidation is a close below the 1-week EM low ($456.59). Top plays: 1) Put spread for defined-risk income, 2) Calendar for vol structure arb, 3) PMCC for longer-term bullish exposure with income.

How to Use These Reports

This directional reflects the market close on March 31, 2026.

What the reports do

Each report translates the same market-close options snapshot into a specific lens such as directional bias, premium-selling posture, flow quality, or earnings setup.

How traders use them

Reports are most useful for narrowing the playbook, surfacing entry and risk context, and deciding which raw data page to inspect next.

What to remember

These are interpretation layers, not execution guarantees. Validate the setup against chain liquidity, expected move, and exposure before sizing risk.

If the report conviction and the raw data disagree, slow down and resolve the mismatch before sizing risk.